AT
Aukera Therapeutics develops RAPTOR inhibitors to treat mTORC1‑related diseases. The company combines deep mTOR biology expertise with an AI‑driven drug discovery engine to address complex, hard‑to‑drug targets. Its preclinical platform aims to translate mTOR inhibition into therapeutic candidates for patient benefit.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Aukera Therapeutics develops RAPTOR inhibitors to treat mTORC1‑related diseases. The company combines deep mTOR biology expertise with an AI‑driven drug discovery engine to address complex, hard‑to‑drug targets. Its preclinical platform aims to translate mTOR inhibition into therapeutic candidates for patient benefit.